Salivary Gland Poorly Differentiated Carcinoma Completed Phase 2 Trials for Dasatinib (DB01254)

IndicationStatusPhase
DBCOND0031192 (Salivary Gland Poorly Differentiated Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00859937Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland TumorsTreatment